The National Council for Prescription Drug Programs’ (NCPDP) Billing Unit Standard (BUS) brings order to pharmaceutical transactions. Between it, the National Drug Code (NDC) and the Structured ...
A US Section 301 probe into Germany's drug pricing could bring tariffs on APIs and finished drugs, raising new supply chain ...
More than 85% of health plan actuaries surveyed for PwC's “Medical Cost Trend: Behind the Numbers 2027” report expect ...
In this week's Pharma Pulse, Europe’s drug pricing standoff intensifies, CMS moves to formalize Medicare negotiation rules, ...
In this week's Pharma Pulse, USP's annual shortages report reveals a sharp rise in drug discontinuations, J&J and Roche ...
A March–June 2026 Hormuz closure disrupted a chokepoint for 20–25% of global maritime oil trade, translating into higher ...
Coverage durability is weakening: many employers cover GLP-1s for obesity today, yet a notable subset expects discontinuation ...
Rapid formulary expansion converts federal web traffic into high-intent DTC referrals to manufacturer-controlled purchasing ...
PwC’s Philip Sclafani discusses rising payer cost exposure, GLP-1 growth, and why pharmacy spending is outpacing medical cost trend heading into 2027. Another factor is the growing pipeline of ...
Codification replaces time-limited guidance authority after the first three cycles, establishing enduring parameters for 2029+ negotiations of up to 20 selected drugs spanning Part B and Part D.
More than 4,200 cell, gene, and RNA therapies are in development, with gene therapies nearly half, and approved CGTs priced $373,000–$4.25 million. Fragmented US payment and delivery systems cannot ...
Behavioral and engagement insights are helping biopharma companies design more personalized patient support programs that improve persistence and long-term outcomes. Standardized patient support ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results